Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept safety study in CVID-associated interstitial lung disease
2015-002491-24Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Mar 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in interstitial lung disease (ILD) and common variable immunodeficiency (CVID), sponsored by Universitätsklinikum Freiburg. Primary endpoint: Number and type of severe infections under treatment. Started Mar 2016; status: completed.
02
Drugs
abatacept
03
Conditions
interstitial lung disease (ILD)common variable immunodeficiency (CVID)
Beyond the preview
Go deeper on 2015-002491-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002491-24.